Our Eurofins Discovery experts can guide you through binding technology complexities to enable assessment of your compounds more precisely and effectively – saving you precious time and costs.
The binding of a ligand to a specific target is an essential requirement for endogenic messengers as well as for exogenic molecules in order to exert physiologically or pharmacologically relevant effects. In drug development research, receptor-ligand binding assays play a critical role in the detection and characterization of molecular interactions with specific targets. Binding assays are vital in the drug discovery process, as they allow for the assessment of affinities and kinetics of test compounds to molecular targets. Conventional methods to measure ligand-receptor binding parameters typically require labeled ligands as probes including radioactive, fluorescent, and luminescence-labeled ligands.
Our scientists have developed industry-leading expertise in radioligand binding assays, a vital tool in drug discovery. These assays are proven essential in key areas ranging from rapidly screen large compound libraries against many molecular targets, to profiling lead series against broad targets list, to assessing selectivity and off-target liability. This approach has been successfully generating new leads, but it carries inherent disadvantages such as expensive synthesis, and lack of availability of radioligands.
Our approach: Harnessing mass spectrometry-based label-free binding assays that are complementary to radioligands and other labeled ligand-binding assays. The advantage:
- Enables confirmation of direct binding of compounds to a native molecular target
- Can be developed more rapidly without utilizing extrinsic labeling
- Eliminates risk of labels interfering with binding events
Access the Eurofins Discovery method of utilizing mass spectrometry binding assays that share all the advantages of sensitive, robust and cost-effective radioligand binding assays.
